Epidemiology of human noroviruses and updates on vaccine development

Current Opinion in Gastroenterology

Volumn 30, Issue 1, 2014, Pages 25-33

  Ramani, Sasirekha ^a   Atmar, Robert L ^a   Estes, Mary K ^a  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

histoblood group antigens; norovirus epidemiology; variants; virus like particle vaccines

Indexed keywords

BLOOD GROUP ANTIGEN; GLYCAN; HISTOBLOOD GROUP ANTIGEN; NOROVIRUS VACCINE; PROTEIN VP1; RNA VACCINE; ROTAVIRUS VACCINE; SINGLE STRANDED RNA; UNCLASSIFIED DRUG; VIRUS LIKE PARTICLE VACCINE;

ACUTE GASTROENTERITIS; ANTIGENIC VARIATION; ANTIGENICITY; CLINICAL TRIAL (TOPIC); DIARRHEA; DISEASE SEVERITY; DRUG DESIGN; DRUG EFFICACY; DRUG SAFETY; EPIDEMIC; EPIDEMIOLOGICAL DATA; FOOD POISONING; GASTROINTESTINAL TRACT; GENETIC VARIABILITY; GENOTYPE; HOSPITALIZATION; HUMAN; IMMUNIZATION; IMMUNOCOMPROMISED PATIENT; IMMUNOGENICITY; INCIDENCE; MEMORY CELL; MORTALITY; MULTIPLEX POLYMERASE CHAIN REACTION; NOROVIRUS; NOROVIRUS INFECTION; PHYLOGENY; PUBLIC HEALTH; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; REVIEW; RISK FACTOR; ROTAVIRUS; ROTAVIRUS INFECTION; SEROEPIDEMIOLOGY; SINGLE DRUG DOSE; VIRAL GASTROENTERITIS; VIRUS LIKE AGENT; VIRUS PATHOGENESIS; VIRUS RECOMBINANT; VIRUS STRAIN;

ACUTE DISEASE; CALICIVIRIDAE INFECTIONS; GASTROENTERITIS; GENOTYPE; HUMANS; NOROVIRUS; PHYLOGENY; VACCINES, VIRUS-LIKE PARTICLE;

EID: 84890432612     PISSN: 02671379     EISSN: 15317056     Source Type: Journal    
DOI: 10.1097/MOG.0000000000000022     Document Type: Review

References (68)

1. Hall AJ, Rosenthal M, Gregoricus N, et al. Incidence of acute gastroenteritis and role of norovirus, Georgia, USA, 2004-2005. Emerg Infect Dis 2011; 17:1381-1388. 2.
2. Hall AJ, Lopman BA, Payne DC, et al. Norovirus disease in the United States. Emerg Infect Dis 2013; 19:1198-1205. Most recent estimates of NoV disease burden in the United States providing incidence rates for deaths, hospitalizations, emergency and outpatient visits and total illnesses.
3. Atmar RL, Estes MK. Norovirus vaccine development: Next steps. Expert Rev Vaccines 2012; 11:1023-1025.
4. Richardson C, Bargatze RF, Goodwin R, et al. Norovirus virus-like particle vaccines for the prevention of acute gastroenteritis. Expert Rev Vaccines 2013; 12:155-167.
5. Kroneman A, Vega E, Vennema H, et al. Proposal for a unified norovirus nomenclature and genotyping. Arch Virol 2013; 158:2059-2068.
6. Mesquita JR, Barclay L, Nascimento MS, et al. Novel norovirus in dogs with diarrhea. Emerg Infect Dis 2010; 16:980-982.
7. Menon VK, George S, Shanti AA, et al. Exposure to human and bovine noroviruses in a birth cohort in southern India from 2002 to 2006. J Clin Microbiol 2013; 51:2391-2395.
8. Zakhour M, Ruvoen-Clouet N, Charpilienne A, et al. The alphaGal epitope of the histo-blood group antigen family is a ligand for bovine norovirus Newbury2 expected to prevent cross-species transmission. PLoS Pathog 2009; 5:e1000504.
9. Zheng DP, Ando T, Fankhauser RL, et al. Norovirus classification and proposed strain nomenclature. Virology 2006; 346:312-323.
10. Eden JS, Tanaka MM, Boni MF, et al. Recombination within the pandemic norovirus GII.4 lineage. J Virol 2013; 87:6270-6282.
11. Iritani N, Vennema H, Siebenga JJ, et al.Genetic analysis of the capsid gene of genotype GII.2 noroviruses. J Virol 2008; 82:7336-7345.
12. Hoa Tran TN, Trainor E, Nakagomi T, et al. Molecular epidemiology of noroviruses associated with acute sporadic gastroenteritis in children: Global distribution of genogroups, genotypes and GII.4 variants. J Clin Virol 2013; 56:185-193.
13. Scallan E, Hoekstra RM, Angulo FJ, et al. Foodborne illness acquired in the United States-major pathogens. Emerg Infect Dis 2011; 17: 7-15.
14. Hall AJ, Wikswo ME, Manikonda K, et al. Acute gastroenteritis surveillance through the National Outbreak Reporting System, United States. Emerg Infect Dis 2013; 19:1305-1309. Systematic surveillance data from National Outbreak Reporting System Network showing that NoVs are the leading cause of outbreaks, illnesses, hospitalizations and deaths.
15. Trivedi TK, Desai R, Hall AJ, et al. Clinical characteristics of norovirusassociated deaths: A systematic literature review. Am J Infect Control 2013; 41:654-657.
16. Bok K, Green KY. Norovirus gastroenteritis in immunocompromised patients. N Engl J Med 2012; 367:2126-2132.
17. Ramani S, Kang G. Viruses causing childhood diarrhoea in the developing world. Curr Opin Infect Dis 2009; 22:477-482.
18. Patel MM, Widdowson MA, Glass RI, et al. Systematic literature review of role of noroviruses in sporadic gastroenteritis. Emerg Infect Dis 2008; 14:1224-1231.
19. Koo HL, Neill FH, Estes MK, et al. Noroviruses: The most common pediatric viral enteric pathogen at a large university hospital after introduction of rotavirus vaccination. J Pediatr Infect Dis Soc 2013; 2:57-60. NoVs are the leading cause of diarrhea hospitalizations in a large pediatric hospital after the introduction of rotavirus vaccines.
20. Williams DJ, Edwards KM, Payne DC, et al. Decline in gastroenteritis- related triage calls after rotavirus vaccine licensure. Pediatrics 2012; 130:e872-e878.
21. Payne DC, Vinje J, Szilagyi PG, et al. Norovirus and medically attended gastroenteritis in U.S. children. N Engl J Med 2013; 368:1121-1130. Prospective surveillance data showing that the burden of NoV disease in children may be higher than previous estimates.
22. Bucardo F, Lindgren PE, Svensson L, et al. Low prevalence of rotavirus and high prevalence of norovirus in hospital and community wastewater after introduction of rotavirus vaccine in Nicaragua. PLoS One 2011; 6:e25962.
23. Kotloff KL, Nataro JP, Blackwelder WC, et al. Burden and aetiology of diarrhoeal disease in infants and young children in developing countries (the Global Enteric Multicenter Study, GEMS): A prospective, case-control study. Lancet 2013; 382:209-222.
24. Tam CC, O'Brien SJ, Tompkins DS, et al. Changes in causes of acute gastroenteritis in the United Kingdom over 15 years: Microbiologic findings from 2 prospective, population-based studies of infectious intestinal disease. Clin Infect Dis 2012; 54:1275-1286. Population studies documenting the increase in NoV burden of disease over time in the United Kingdom.
25. Bartsch SM, Lopman BA, Hall AJ, et al. The potential economic value of a human norovirus vaccine for the United States. Vaccine 2012; 30:7097-7104. Provides estimates of the economic impact of NoV vaccines based on the cost of vaccine and duration of effectiveness.
26. Matthews JE, Dickey BW, Miller RD, et al. The epidemiology of published norovirus outbreaks: A review of risk factors associated with attack rate and genogroup. Epidemiol Infect 2012; 140:1161-1172.
27. Lysen M, Thorhagen M, Brytting M, et al. Genetic diversity among food-borne and waterborne norovirus strains causing outbreaks in Sweden. J Clin Microbiol 2009; 47:2411-2418.
28. Seitz SR, Leon JS, Schwab KJ, et al. Norovirus infectivity in humans and persistence in water. Appl Environ Microbiol 2011; 77:6884-6888.
29. Desai R, Hembree CD, Handel A, et al. Severe outcomes are associated with genogroup 2 genotype 4 norovirus outbreaks: A systematic literature review. Clin Infect Dis 2012; 55:189-193.
30. Gastanaduy PA, Hall AJ, Curns AT, et al. Burden of norovirus gastroenteritis in the ambulatory setting-United States. J Infect Dis 2013; 207:1058-1065.
31. Van Beek J, Ambert-Balay K, Botteldoorn N, et al. Indications for worldwide increased norovirus activity associated with emergence of a new variant of genotype II. 4, late. Euro Surveill 2013; 18:8-9. Reports of the emergence of the new GII.4 variant Sydney 2012 that has resulted in increased NoV epidemics worldwide.
32. Leshem E, Wikswo M, Barclay L, et al. Effects and clinical significance of GII.4 Sydney norovirus, United States 2012-2013. Emerg Infect Dis 2013; 19:1231-1238.
33. Bull RA, White PA. Mechanisms of GII.4 norovirus evolution. Trends Microbiol 2011; 19:233-240.
34. Debbink K, Donaldson EF, Lindesmith LC, et al. Genetic mapping of a highly variable norovirus GII.4 blockade epitope: Potential role in escape from human herd immunity. J Virol 2012; 86:1214-1226.
35. Lindesmith LC, Beltramello M, Donaldson EF, et al. Immunogenetic mechanisms driving norovirus GII.4 antigenic variation. PLoS Pathog 2012; 8:e1002705.
36. Atmar RL, Bernstein DI, Harro CD, et al. Norovirus vaccine against experimental human Norwalk Virus illness. N Engl J Med 2011; 365:2178-2187.
37. Czako R, Atmar RL, Opekun AR, et al. Serum hemagglutination inhibition activity correlates with protection from gastroenteritis in persons infected with Norwalk virus. Clin Vaccine Immunol 2012; 19:284-287.
38. Reeck A, Kavanagh O, Estes MK, et al. Serological correlate of protection against norovirus-induced gastroenteritis. J Infect Dis 2010; 202:1212-1218.
39. Carlsson B, Kindberg E, Buesa J, et al. The G428A nonsense mutation in FUT2 provides strong but not absolute protection against symptomatic GII.4 Norovirus infection. PLoS One 2009; 4:e5593.
40. de Rougemont A, Ruvoen-Clouet N, Simon B, et al. Qualitative and quantitative analysis of the binding of GII.4 norovirus variants onto human blood group antigens. J Virol 2011; 85:4057-4070.
41. Debbink K, Lindesmith LC, Donaldson EF, et al. Emergence of new pandemic GII.4 Sydney norovirus strain correlates with escape from herd immunity. J Infect Dis 2013. [Epub ahead of print]
42. Lindesmith LC, Donaldson EF, Lobue AD, et al. Mechanisms ofGII.4 norovirus persistence in human populations. PLoS Med 2008; 5:e31.
43. Fiege B, Rademacher C, Cartmell J, et al. Molecular details of the recognition of blood group antigens by a human norovirus as determined by STD NMR spectroscopy. Angew Chem Int Ed Engl 2012; 51:928-932.
44. Nasir W, Frank M, Koppisetty CA, et al. Lewis histo-blood group alpha1,3/alpha1,4 fucose residues may both mediate binding to GII.4 noroviruses. Glycobiology 2012; 22:1163-1172.
45. Jin M, He Y, Li H, et al. Two gastroenteritis outbreaks caused by GII Noroviruses: Host susceptibility and HBGA phenotypes. PLoS One 2013; 8:e58605. An outbreak of GII.4 in China including symptomatic infections among nonsecretors. The NoV genotype was highly similar to ones binding nonsecretor HBGAs in vitro.
46. Nordgren J, Nitiema LW, Ouermi D, et al. Host genetic factors affect susceptibility to norovirus infections in Burkina Faso. PloS One 2013; 8:e69557.
47. Shirato H, Ogawa S, Ito H, et al. Noroviruses distinguish between type 1 and type 2 histo-blood group antigens for binding. J Virol 2008; 82:10756-10767.
48. Kubota T, Kumagai A, Ito H, et al. Structural basis for the recognition of Lewis antigens by genogroup I norovirus. J Virol 2012; 86:11138-11150. Structural studies showing how nonsecretor HBGA binding occurs in a GI virus predicting that a longer P loop and a single amino change at position 389 may alter HBGA binding specificity.
49. Nordgren J, Kindberg E, Lindgren PE, et al. Norovirus gastroenteritis outbreak with a secretor-independent susceptibility pattern, Sweden. Emerg Infect Dis 2010; 16:81-87.
50. Leshem E, Barclay L, Wikswo M, et al. Genotype GI.6 Norovirus, United States. Emerg Infect Dis 2013; 19:1317-1320.
51. Hasing ME, Lee BE, Preiksaitis JK, et al. Emergence of a new norovirus GII.4 variant and changes in the historical biennial pattern of norovirus outbreak activity in Alberta, Canada, from 2008 to 2013. J Clin Microbiol 2013; 51:2204-2211.
52. Bull RA, Eden JS, Luciani F, et al. Contribution of intra-and interhost dynamics to norovirus evolution. J Virol 2012; 86:3219-3229.
53. Mattison K, Shukla A, Cook A, et al. Human noroviruses in swine and cattle. Emerg Infect Dis 2007; 13:1184-1188.
54. Bui T, Kocher J, Li Y, et al. Median infectious dose of human norovirus GII.4 in gnotobiotic pigs is decreased by simvastatin treatment and increased by age. J Gen Virol 2013; 94 (Pt 9):2005-2016.
55. Taube S, Kolawole AO, Hohne M, et al. A mouse model for human norovirus. mBio 2013; 4:e00450-13; Epub 2013/07/19.
56. Souza M, Azevedo MS, Jung K, et al. Pathogenesis and immune responses in gnotobiotic calves after infection with the genogroup II.4-HS66 strain of human norovirus. J Virol 2008; 82:1777-1786.
57. Jiang X, Wang M, Graham DY, et al. Expression, self-assembly, and antigenicity of the Norwalk virus capsid protein. J Virol 1992; 66:6527-6532.
58. Estes MK, Ball JM, Guerrero RA, et al. Norwalk virus vaccines: Challenges and progress. J Infect Dis 2000; 181 (Suppl 2):S367-S373.
59. Ball JM, Graham DY, Opekun AR, et al. Recombinant Norwalk virus-like particles given orally to volunteers: Phase I study. Gastroenterology 1999; 117:40-48.
60. Tacket CO, Sztein MB, Losonsky GA, et al. Humoral, mucosal, and cellular immune responses to oral Norwalk virus-like particles in volunteers. Clin Immunol 2003; 108:241-247.
61. El-Kamary SS, Pasetti MF, Mendelman PM, et al. Adjuvanted intranasal Norwalk virus-like particle vaccine elicits antibodies and antibody-secreting cells that express homing receptors for mucosal and peripheral lymphoid tissues. J Infect Dis 2010; 202:1649-1658.
62. Ramirez K, Wahid R, Richardson C, et al. Intranasal vaccination with an adjuvanted Norwalk virus-like particle vaccine elicits antigen-specific B memory responses in human adult volunteers. Clin Immunol 2012; 144:98-108. Proof of principle that antigen-specific memory B cells are elicited postvaccination with the VLP vaccine.
63. Parra GI, Bok K, Taylor R, et al. Immunogenicity and specificity of norovirus Consensus GII.4 virus-like particles in monovalent and bivalent vaccine formulations. Vaccine 2012; 30:3580-3586. Described the development of a GII.4 consenus VLP to be used as a vaccine targeting the predominant NoV genotype that shows antigenic variation over time.
64. Frey SE, Treanor JJ, Atmar RL, et al. Dose escalation trial of the safety and immunogenicity of a bivalent Norovirus virus-like particle vaccine administered by the intramuscular route. Presented at 49th Annual Meeting of the Infectious Disease Society of America (IDSA) Boston, MA, USA, 20-23 October 2011.
65. Treanor JJ, Frey S, Gormley R. Safety and immunogenicity of an intramuscular Norovirus VLP vaccine. Presented at 52nd Interscience Conference on Antimicrobial Agents and Chemotherapy San Francisco, CA, USA, 9-12 September 2012.
66. Frenck R, Bernstein DI, Xia M, et al. Predicting susceptibility to norovirus GII.4 by use of a challenge model involving humans. J Infect Dis 2012; 206:1386-1393. Development and evaluation of a GII.4 challenge pool will be important for testing efficacy of the VLP vaccines against GII.4 NoVs.
67. Simmons K, Gambhir M, Leon J, et al. Duration of immunity to norovirus gastroenteritis. Emerg Infect Dis 2013; 19:1260-1267. Mathematical modelling of NoV transmission in the community resulted in the estimate of the duration of NoV immunity to be between 4.1 and 8.7 years. This is longer than what has been thought previously (6 months to 2 years).
68. Blazevic V, Lappalainen S, Nurminen K, et al. Norovirus VLPs and rotavirus VP6 protein as combined vaccine for childhood gastroenteritis. Vaccine 2011; 29:8126-8133.